Skip to main content
Top
Published in: Diabetologia 5/2006

01-05-2006 | Article

Prevalence and correlates of post-prandial hyperglycaemia in a large sample of patients with type 2 diabetes mellitus

Authors: E. Bonora, G. Corrao, V. Bagnardi, A. Ceriello, M. Comaschi, P. Montanari, J. B. Meigs

Published in: Diabetologia | Issue 5/2006

Login to get access

Abstract

Aims/hypothesis

Post-prandial glucose may be a risk factor for cardiovascular disease and chronic diabetic complications. We tested the hypothesis that post-prandial hyperglycaemia is common in type 2 diabetes, even among patients in apparently good glycaemic control, and that simple clinical characteristics identify subsets of diabetic patients with frequent post-prandial hyperglycaemia.

Subjects and methods

Three self-assessed daily blood glucose profiles over a 1-week period, including 18 glucose readings before and 2 h after meals, were obtained from 3,284 unselected outpatients (men 51%; age 63±10 years) with non-insulin-treated type 2 diabetes mellitus attending 500 different diabetes clinics operating throughout Italy.

Results

A post-prandial blood glucose value >8.89 mmol/l (160 mg/dl) was recorded at least once in 84% of patients, and 81% of patients had at least one Δglucose ≥2.22 mmol/l (40 mg/dl). Among patients with apparently good metabolic control, 38% had >40% of post-prandial blood glucose readings >8.89 mmol/l (≥4 of 9 meals in total), and 36% had >40% Δglucose ≥2.22 mmol/l. In multivariate analysis adjusted for pre-prandial glucose levels, older age, longer duration of diabetes, absence of obesity, hyperlipidaemia and hypertension, as well as treatment with sulfonylureas, were significantly associated with greater glucose excursions after meals.

Conclusions/interpretation

These results indicate that post-prandial hyperglycaemia is a very frequent phenomenon in patients with type 2 diabetes mellitus on active treatment; can occur even when metabolic control is apparently good; and can be predicted by simple clinical features.
Literature
1.
go back to reference Gerich JE (2003) Clinical significance, pathogenesis, and management of postprandial hyperglycaemia. Arch Intern Med 163:1306–1316PubMed Gerich JE (2003) Clinical significance, pathogenesis, and management of postprandial hyperglycaemia. Arch Intern Med 163:1306–1316PubMed
2.
go back to reference Haffner SM (1998) The importance of hyperglycaemia in the nonfasting state to the development of cardiovascular disease. Endocr Rev 19:583–592PubMed Haffner SM (1998) The importance of hyperglycaemia in the nonfasting state to the development of cardiovascular disease. Endocr Rev 19:583–592PubMed
3.
go back to reference Ceriello A (2003) The possible role of post-prandial hyperglycaemia in the pathogenesis of diabetic complications. Diabetologia 46 (Suppl 1):M9–M16PubMed Ceriello A (2003) The possible role of post-prandial hyperglycaemia in the pathogenesis of diabetic complications. Diabetologia 46 (Suppl 1):M9–M16PubMed
4.
go back to reference Bonora E, Muggeo M (2001) Post-prandial blood glucose as a risk factor for cardiovascular disease in type 2 diabetes. The epidemiological evidence. Diabetologia 44:2107–2114PubMed Bonora E, Muggeo M (2001) Post-prandial blood glucose as a risk factor for cardiovascular disease in type 2 diabetes. The epidemiological evidence. Diabetologia 44:2107–2114PubMed
5.
go back to reference Hanefeld M, Fischer S, Julius U et al (1996) Risk factors for myocardial infarction and death in newly detected NIDDM: the Diabetes Intervention Study, 11-year follow-up. Diabetologia 39:1577–1583PubMed Hanefeld M, Fischer S, Julius U et al (1996) Risk factors for myocardial infarction and death in newly detected NIDDM: the Diabetes Intervention Study, 11-year follow-up. Diabetologia 39:1577–1583PubMed
6.
go back to reference Bonora E (2002) Postprandial peaks as a risk factor for cardiovascular disease: epidemiological perspectives. Int J Clin Pract Suppl 129:5–11PubMed Bonora E (2002) Postprandial peaks as a risk factor for cardiovascular disease: epidemiological perspectives. Int J Clin Pract Suppl 129:5–11PubMed
7.
go back to reference Cavalot F, Petrelli A, Traversa M et al (2005) Postprandial blood glucose is a stronger predictor of cardiovascular events than fasting blood glucose in type 2 diabetes mellitus, particularly in women. J Clin Endocrinol Metab [Epub ahead of print] Cavalot F, Petrelli A, Traversa M et al (2005) Postprandial blood glucose is a stronger predictor of cardiovascular events than fasting blood glucose in type 2 diabetes mellitus, particularly in women. J Clin Endocrinol Metab [Epub ahead of print]
8.
go back to reference The DECODE study group on behalf of the European Diabetes Epidemiology Group (2001) Glucose tolerance and cardiovascular mortality. Comparison of fasting and 2-h diagnostic criteria. Arch Intern Med 161:397–404 The DECODE study group on behalf of the European Diabetes Epidemiology Group (2001) Glucose tolerance and cardiovascular mortality. Comparison of fasting and 2-h diagnostic criteria. Arch Intern Med 161:397–404
9.
go back to reference Meigs JB, Nathan DM, D’Agostino RB Sr, Wilson PW (2002) Fasting and post-challenge glycaemia and cardiovascular risk: the Framingham Offspring Study. Diabetes Care 25:1845–1850PubMed Meigs JB, Nathan DM, D’Agostino RB Sr, Wilson PW (2002) Fasting and post-challenge glycaemia and cardiovascular risk: the Framingham Offspring Study. Diabetes Care 25:1845–1850PubMed
10.
go back to reference American Diabetes Association (2001) Post-prandial blood glucose. Diabetes Care 24:775–778 American Diabetes Association (2001) Post-prandial blood glucose. Diabetes Care 24:775–778
11.
go back to reference American Diabetes Association (2005) Standard of medical care for patients with diabetes mellitus. Diabetes Care 28 (Suppl 1):S4–S40 American Diabetes Association (2005) Standard of medical care for patients with diabetes mellitus. Diabetes Care 28 (Suppl 1):S4–S40
12.
go back to reference European Diabetes Policy Group (1999) A desktop guide to type 2 diabetes mellitus. Diabetic Med 16:716–730 European Diabetes Policy Group (1999) A desktop guide to type 2 diabetes mellitus. Diabetic Med 16:716–730
13.
go back to reference Bonora E, Calcaterra F, Lombardi S et al (2001) Plasma glucose levels throughout the day and HbA1c interrelationships in type 2 diabetes. Implications for treatment and monitoring of metabolic control. Diabetes Care 24:2023–2029PubMed Bonora E, Calcaterra F, Lombardi S et al (2001) Plasma glucose levels throughout the day and HbA1c interrelationships in type 2 diabetes. Implications for treatment and monitoring of metabolic control. Diabetes Care 24:2023–2029PubMed
14.
go back to reference Avignon A, Radauceanu A, Monnier L (1997) Non-fasting plasma glucose is a better marker of diabetic control than fasting plasma glucose in type 2 diabetes. Diabetes Care 20:1822–1826PubMed Avignon A, Radauceanu A, Monnier L (1997) Non-fasting plasma glucose is a better marker of diabetic control than fasting plasma glucose in type 2 diabetes. Diabetes Care 20:1822–1826PubMed
15.
go back to reference Monnier L, Colette C, Rabasa-Lhoret R et al (2002) Morning hyperglycaemic excursions. A constant failure in the metabolic control of non-insulin-using patients with type 2 diabetes. Diabetes Care 25:737–741PubMed Monnier L, Colette C, Rabasa-Lhoret R et al (2002) Morning hyperglycaemic excursions. A constant failure in the metabolic control of non-insulin-using patients with type 2 diabetes. Diabetes Care 25:737–741PubMed
16.
go back to reference Monnier L, Lapinski H, Colette C (2003) Contributions of fasting and postprandial plasma glucose increments to the overall diurnal hyperglycaemia of type 2 diabetic patients: variations with increasing levels of HbA1c. Diabetes Care 26:881–885PubMed Monnier L, Lapinski H, Colette C (2003) Contributions of fasting and postprandial plasma glucose increments to the overall diurnal hyperglycaemia of type 2 diabetic patients: variations with increasing levels of HbA1c. Diabetes Care 26:881–885PubMed
17.
go back to reference Meigs JB, Nathan DM, D’Agostino RB Sr, Wilson PW; Framingham Offspring Study (2002) Fasting and postchallenge glycaemia and cardiovascular disease risk: the Framingham Offspring Study. Diabetes Care 25:1845–1850PubMed Meigs JB, Nathan DM, D’Agostino RB Sr, Wilson PW; Framingham Offspring Study (2002) Fasting and postchallenge glycaemia and cardiovascular disease risk: the Framingham Offspring Study. Diabetes Care 25:1845–1850PubMed
18.
go back to reference Erlinger TP, Brancati FL (2001) Postchallenge hyperglycaemia in a national sample of US adults with type 2 diabetes. Diabetes Care 24:1734–1738PubMed Erlinger TP, Brancati FL (2001) Postchallenge hyperglycaemia in a national sample of US adults with type 2 diabetes. Diabetes Care 24:1734–1738PubMed
19.
go back to reference Harris MI, Cowie CC, Howie LJ (1993) Self-monitoring of blood glucose by adults with diabetes in the United States population. Diabetes Care 16:1116–1123PubMed Harris MI, Cowie CC, Howie LJ (1993) Self-monitoring of blood glucose by adults with diabetes in the United States population. Diabetes Care 16:1116–1123PubMed
20.
go back to reference McGill JB, Cole TG, Nowatzke W et al (2004) Circulating 1,5-anhydroglucitol levels in adult patients with diabetes reflect longitudinal changes of glycaemia: a US trial of the GlycoMark assay. Diabetes Care 27:1859–1865PubMed McGill JB, Cole TG, Nowatzke W et al (2004) Circulating 1,5-anhydroglucitol levels in adult patients with diabetes reflect longitudinal changes of glycaemia: a US trial of the GlycoMark assay. Diabetes Care 27:1859–1865PubMed
21.
go back to reference Wolever TMS, Chiasson JL, Csima A et al (1998) Variation of post-prandial plasma glucose, palatability and symptoms associated with a standardized mixed meal versus 75 g oral glucose. Diabetes Care 21:336–340PubMed Wolever TMS, Chiasson JL, Csima A et al (1998) Variation of post-prandial plasma glucose, palatability and symptoms associated with a standardized mixed meal versus 75 g oral glucose. Diabetes Care 21:336–340PubMed
22.
go back to reference University Group Diabetes Program (1982) Effects of hypoglycaemic agents on vascular complications in patients with adult-onset diabetes. VIII. Evaluation of insulin therapy. Final report. Diabetes 31 (Suppl 5):1–26 University Group Diabetes Program (1982) Effects of hypoglycaemic agents on vascular complications in patients with adult-onset diabetes. VIII. Evaluation of insulin therapy. Final report. Diabetes 31 (Suppl 5):1–26
23.
go back to reference Abraira C, Colwell JA, Nuttall FQ et al (1997) Cardiovascular events and correlates in the Veteran Affairs Diabetes Feasibility Trial. Veterans Affairs Cooperative Study on glycemic control and complications in type 2 diabetes (VA CSDM). Arch Intern Med 157:181–188PubMed Abraira C, Colwell JA, Nuttall FQ et al (1997) Cardiovascular events and correlates in the Veteran Affairs Diabetes Feasibility Trial. Veterans Affairs Cooperative Study on glycemic control and complications in type 2 diabetes (VA CSDM). Arch Intern Med 157:181–188PubMed
24.
go back to reference UK Prospective Diabetes Study Group (1998) Intensive blood-glucose control with sulphonylureas or insulin compared with conventional treatment and risk of complications in patients with type 2 diabetes (UKPDS 33). Lancet 352:837–853 UK Prospective Diabetes Study Group (1998) Intensive blood-glucose control with sulphonylureas or insulin compared with conventional treatment and risk of complications in patients with type 2 diabetes (UKPDS 33). Lancet 352:837–853
25.
go back to reference Malmberg K for the DIGAMI Study Group (1997) Prospective randomised study of intensive insulin treatment on long term survival after acute myocardial infraction in patients with diabetes mellitus. BMJ 314:1512–1515PubMed Malmberg K for the DIGAMI Study Group (1997) Prospective randomised study of intensive insulin treatment on long term survival after acute myocardial infraction in patients with diabetes mellitus. BMJ 314:1512–1515PubMed
26.
go back to reference Shichiri M, Kishikawa H, Ohkubo Y, Wake N (2000) Long term results of the Kumamoto Study on optimal diabetes control in type 2 diabetic patients. Diabetes Care 23 (Suppl 2):B21–B29PubMed Shichiri M, Kishikawa H, Ohkubo Y, Wake N (2000) Long term results of the Kumamoto Study on optimal diabetes control in type 2 diabetic patients. Diabetes Care 23 (Suppl 2):B21–B29PubMed
27.
go back to reference Chiasson JL, Josse RG, Gomis R, Hanefeld M, Karasik A, Laakso M, STOP–NIDDM Trial Research Group (2003) Acarbose treatment and the risk of cardiovascular disease and hypertension in patients with impaired glucose tolerance: the STOP–NIDDM trial. JAMA 290:486–494PubMed Chiasson JL, Josse RG, Gomis R, Hanefeld M, Karasik A, Laakso M, STOP–NIDDM Trial Research Group (2003) Acarbose treatment and the risk of cardiovascular disease and hypertension in patients with impaired glucose tolerance: the STOP–NIDDM trial. JAMA 290:486–494PubMed
28.
go back to reference Esposito K, Giugliano D, Nappo F, Martella and the Campanian Postprandial Hyperglycaemia Study Group (2004) Regression of carotid atherosclerosis by control of postprandial hyperglycaemia in type 2 diabetes mellitus. Circulation 110:214–219PubMed Esposito K, Giugliano D, Nappo F, Martella and the Campanian Postprandial Hyperglycaemia Study Group (2004) Regression of carotid atherosclerosis by control of postprandial hyperglycaemia in type 2 diabetes mellitus. Circulation 110:214–219PubMed
29.
go back to reference Pirags V, Assert R, Haupt K, Schatz H, Pfeiffer A (1996) Activation of human platelet protein kinase C-beta 2 in vivo in response to acute hyperglycaemia. Exp Clin Endocrinol Diabetes 104:431–440CrossRefPubMed Pirags V, Assert R, Haupt K, Schatz H, Pfeiffer A (1996) Activation of human platelet protein kinase C-beta 2 in vivo in response to acute hyperglycaemia. Exp Clin Endocrinol Diabetes 104:431–440CrossRefPubMed
30.
go back to reference Giugliano D, Marfella R, Coppola L et al (1997) Vascular effects of acute hyperglycaemia in humans are reversed by l-arginine: evidence for reduced availability of nitric oxide during hyperglycaemia. Circulation 95:1783–1790PubMed Giugliano D, Marfella R, Coppola L et al (1997) Vascular effects of acute hyperglycaemia in humans are reversed by l-arginine: evidence for reduced availability of nitric oxide during hyperglycaemia. Circulation 95:1783–1790PubMed
31.
go back to reference Williams SB, Goldfine AB, Timimi FK et al (1998) Acute hyperglycaemia attenuates endothelium-dependent vasodilatation in humans in vivo. Circulation 97:1695–1701PubMed Williams SB, Goldfine AB, Timimi FK et al (1998) Acute hyperglycaemia attenuates endothelium-dependent vasodilatation in humans in vivo. Circulation 97:1695–1701PubMed
32.
go back to reference Marfella R, Esposito K, Giunta R et al (2000) Circulating adhesion molecules in humans: role of hyperglycaemia and hyperinsulinemia. Circulation 101:2247–2251PubMed Marfella R, Esposito K, Giunta R et al (2000) Circulating adhesion molecules in humans: role of hyperglycaemia and hyperinsulinemia. Circulation 101:2247–2251PubMed
33.
go back to reference Shige H, Ishikawa T, Suzukawa M et al (1999) Endothelium-dependent flow-mediated vasodilation in the post-prandial state in type 2 diabetes mellitus. Am J Cardiol 84:1272–1274PubMed Shige H, Ishikawa T, Suzukawa M et al (1999) Endothelium-dependent flow-mediated vasodilation in the post-prandial state in type 2 diabetes mellitus. Am J Cardiol 84:1272–1274PubMed
34.
go back to reference Kawano H, Motoyama T, Hirashima O et al (1999) Hyperglycaemia rapidly suppresses flow-mediated endothelium-dependent vasodilation of brachial artery. J Am Coll Cardiol 34:146–154PubMed Kawano H, Motoyama T, Hirashima O et al (1999) Hyperglycaemia rapidly suppresses flow-mediated endothelium-dependent vasodilation of brachial artery. J Am Coll Cardiol 34:146–154PubMed
35.
go back to reference Ceriello A, Giacomello R, Stel G et al (1995) Hyperglycaemia-induced thrombin formation in diabetes. The possible role of oxidative stress. Diabetes 44:924–928PubMed Ceriello A, Giacomello R, Stel G et al (1995) Hyperglycaemia-induced thrombin formation in diabetes. The possible role of oxidative stress. Diabetes 44:924–928PubMed
36.
go back to reference Ceriello A, Taboga C, Tonutti L et al (2002) Evidence for an independent and cumulative effect of post-prandial hypertriglyceridemia and hyperglycaemia on endothelial dysfunction and oxidative stress generation: effect of short- and long-term simvastatin treatment. Circulation 106:1211–1218PubMed Ceriello A, Taboga C, Tonutti L et al (2002) Evidence for an independent and cumulative effect of post-prandial hypertriglyceridemia and hyperglycaemia on endothelial dysfunction and oxidative stress generation: effect of short- and long-term simvastatin treatment. Circulation 106:1211–1218PubMed
37.
go back to reference Li W, Liu X, Yanoff M, Cohen S, Ye X (1996) Cultured retinal capillary pericytes die by apoptosis after an abrupt fluctuation from high to low glucose levels: a comparative study with retinal capillary endothelial cells. Diabetologia 39:537–547PubMed Li W, Liu X, Yanoff M, Cohen S, Ye X (1996) Cultured retinal capillary pericytes die by apoptosis after an abrupt fluctuation from high to low glucose levels: a comparative study with retinal capillary endothelial cells. Diabetologia 39:537–547PubMed
38.
go back to reference Takeuchi A, Throckmorton DC, Brodgen AP, Yoshizawa N, Rasmussen H, Kashgarian M (1995) Periodic high extracellular glucose enhances production of collagens III and IV by mesangial cells. Am J Physiol 268:F13–F19PubMed Takeuchi A, Throckmorton DC, Brodgen AP, Yoshizawa N, Rasmussen H, Kashgarian M (1995) Periodic high extracellular glucose enhances production of collagens III and IV by mesangial cells. Am J Physiol 268:F13–F19PubMed
39.
go back to reference Porta M, Molinatti PA, Dosso AA, Williams FM, Brooks RA, Kohner EM (1994) Growth of bovine retinal pericytes and endothelial cells in high hexose concentrations. Diabetes Metab 20:25–30 Porta M, Molinatti PA, Dosso AA, Williams FM, Brooks RA, Kohner EM (1994) Growth of bovine retinal pericytes and endothelial cells in high hexose concentrations. Diabetes Metab 20:25–30
40.
go back to reference Wolffenbuttel BHR, Landgraf R on behalf of the Dutch and German Repaglinide Study Group (1999) A 1-year multicenter randomized double-blind comparison of repaglinide and glyburide for the treatment of type 2 diabetes. Diabetes Care 22:463–467PubMed Wolffenbuttel BHR, Landgraf R on behalf of the Dutch and German Repaglinide Study Group (1999) A 1-year multicenter randomized double-blind comparison of repaglinide and glyburide for the treatment of type 2 diabetes. Diabetes Care 22:463–467PubMed
41.
go back to reference Gribble FM, Manley SE, Levy JC (2001) Randomized dose ranging study of the reduction of fasting and post-prandial glucose in type 2 diabetes by nateglinide. Diabetes Care 24:1221–1225PubMed Gribble FM, Manley SE, Levy JC (2001) Randomized dose ranging study of the reduction of fasting and post-prandial glucose in type 2 diabetes by nateglinide. Diabetes Care 24:1221–1225PubMed
42.
go back to reference Horton ES, Clinkingbeard C, Gatlin M, Foley J, Mallows S, Shen S (2000) Nateglinide alone and in combination with metformin improves glycemic control by reducing mealtime glucose levels in type 2 diabetes. Diabetes Care 23:1660–1665PubMed Horton ES, Clinkingbeard C, Gatlin M, Foley J, Mallows S, Shen S (2000) Nateglinide alone and in combination with metformin improves glycemic control by reducing mealtime glucose levels in type 2 diabetes. Diabetes Care 23:1660–1665PubMed
43.
go back to reference Fonseca V, Grunberger G, Gupta S, Shen S, Foley JE (2003) Addition of nateglinide to rosiglitazone monotherapy suppresses mealtime hyperglycaemia and improves overall glycemic control. Diabetes Care 26:1685–1690PubMed Fonseca V, Grunberger G, Gupta S, Shen S, Foley JE (2003) Addition of nateglinide to rosiglitazone monotherapy suppresses mealtime hyperglycaemia and improves overall glycemic control. Diabetes Care 26:1685–1690PubMed
44.
go back to reference Anderson JH, Brunelle R, Koivisto VA et al (1997) Insulin analogue treatment reduces post-prandial hyperglycaemia and frequency of hypoglycaemia in IDDM patients. Diabetes 46:265–270PubMed Anderson JH, Brunelle R, Koivisto VA et al (1997) Insulin analogue treatment reduces post-prandial hyperglycaemia and frequency of hypoglycaemia in IDDM patients. Diabetes 46:265–270PubMed
45.
go back to reference Nielsen FS, Jorgensen LN, Ipsen M, Voldsgaard AI, Parving HH (1995) Long-term comparison of insulin analogue B10Asp and soluble human insulin in IDDM patients on a basal/bolus insulin regimen. Diabetologia 38:592–598PubMed Nielsen FS, Jorgensen LN, Ipsen M, Voldsgaard AI, Parving HH (1995) Long-term comparison of insulin analogue B10Asp and soluble human insulin in IDDM patients on a basal/bolus insulin regimen. Diabetologia 38:592–598PubMed
46.
go back to reference Ciofetta M, Lalli C, Del Sindaco P et al (1999) Contribution of post-prandial versus interprandial blood glucose to HbA1c in type 1 diabetes on physiologic intensive therapy with lispro insulin at mealtime. Diabetes Care 22:795–800PubMed Ciofetta M, Lalli C, Del Sindaco P et al (1999) Contribution of post-prandial versus interprandial blood glucose to HbA1c in type 1 diabetes on physiologic intensive therapy with lispro insulin at mealtime. Diabetes Care 22:795–800PubMed
Metadata
Title
Prevalence and correlates of post-prandial hyperglycaemia in a large sample of patients with type 2 diabetes mellitus
Authors
E. Bonora
G. Corrao
V. Bagnardi
A. Ceriello
M. Comaschi
P. Montanari
J. B. Meigs
Publication date
01-05-2006
Publisher
Springer-Verlag
Published in
Diabetologia / Issue 5/2006
Print ISSN: 0012-186X
Electronic ISSN: 1432-0428
DOI
https://doi.org/10.1007/s00125-006-0203-x

Other articles of this Issue 5/2006

Diabetologia 5/2006 Go to the issue
Live Webinar | 27-06-2024 | 18:00 (CEST)

Keynote webinar | Spotlight on medication adherence

Live: Thursday 27th June 2024, 18:00-19:30 (CEST)

WHO estimates that half of all patients worldwide are non-adherent to their prescribed medication. The consequences of poor adherence can be catastrophic, on both the individual and population level.

Join our expert panel to discover why you need to understand the drivers of non-adherence in your patients, and how you can optimize medication adherence in your clinics to drastically improve patient outcomes.

Prof. Kevin Dolgin
Prof. Florian Limbourg
Prof. Anoop Chauhan
Developed by: Springer Medicine
Obesity Clinical Trial Summary

At a glance: The STEP trials

A round-up of the STEP phase 3 clinical trials evaluating semaglutide for weight loss in people with overweight or obesity.

Developed by: Springer Medicine